Vor Biopharma (NASDAQ:VOR) Trading Up 6.1% - Still a Buy?

Key Points

• Vor Biopharma shares rose 6.1% to about $23.23, despite trading volume falling 49% below its average.
• Analyst sentiment is broadly positive, with a consensus rating of “Moderate Buy” and an average price target of $43.38; Wedbush raised its target to $27 while maintaining a neutral rating.
• The clinical-stage biotech missed its latest earnings estimate, reporting a quarterly loss of $0.80 per share versus the expected $0.69 loss. Institutional investors own a substantial 97.29% of the company.

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report)'s stock price rose 6.1% during trading on Tuesday . The company traded as high as $23.41 and last traded at $23.2250. 532,604 shares changed hands during trading, a decline of 49% from the average daily volume of 1,048,599 shares. The stock had previously closed at $21.89.

Analyst Upgrades and Downgrades

VOR has been the topic of several research reports. Wedbush upped their price target on Vor Biopharma from $18.00 to $27.00 and gave the company a "neutral" rating in a research report on Wednesday, August 12th. Weiss Ratings upgraded shares of Vor Biopharma from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Monday, September 14th. Finally, Wall Street Zen raised shares of Vor Biopharma from a "sell" rating to a "hold" rating in a research report on Saturday, August 15th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, Vor Biopharma has a consensus rating of "Moderate Buy" and an average target price of $43.38.

Vor Biopharma Trading Up 4.2%

The firm's 50-day moving average price is $22.01 and its 200 day moving average price is $17.72.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.11). On average, research analysts expect that Vor Biopharma Inc. will post -2.56 EPS for the current fiscal year.

Hedge Funds Weigh In On Vor Biopharma

Several large investors have recently made changes to their positions in the business. Fcpm Iii Services B.V. raised its position in Vor Biopharma by 852.8% during the fourth quarter. Fcpm Iii Services B.V. now owns 3,617,354 shares of the company's stock valued at $47,315,000 after buying an additional 3,237,714 shares during the period. Frazier Life Sciences Management L.P. purchased a new stake in shares of Vor Biopharma during the 4th quarter worth about $33,275,000. NEXTBio Capital Management LP acquired a new stake in shares of Vor Biopharma during the 4th quarter valued at about $13,080,000. Braidwell LP lifted its holdings in shares of Vor Biopharma by 22.8% during the 2nd quarter. Braidwell LP now owns 573,104 shares of the company's stock valued at $10,551,000 after buying an additional 106,330 shares during the last quarter. Finally, Findell Capital Management LLC bought a new stake in shares of Vor Biopharma in the 4th quarter valued at approximately $3,021,000. Institutional investors own 97.29% of the company's stock.

Vor Biopharma Company Profile

Vor Biopharma Inc is a clinical-stage biotechnology company focused on developing treatments for patients with hematologic malignancies, including acute myeloid leukemia (AML). The company combines engineered hematopoietic stem cell therapies with targeted cancer medicines in an effort to improve the selectivity and effectiveness of treatment.

Vor's lead program, trem-cel (formerly known as VOR33), is an investigational gene-edited hematopoietic stem cell therapy designed to eliminate the CD33 protein from blood-forming stem cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.